B7-1 and PD-1 compete for binding to PD-L1.

Slides:



Advertisements
Similar presentations
IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.
Advertisements

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Figure 2 GlyR antibody binding
Triggering PD-1 in B cells suppresses tumor-specific immunity and promotes disease progression. Triggering PD-1 in B cells suppresses tumor-specific immunity.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.
Cetuximab treatment increases IFNγ receptor 1 expression.
Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.
The absence of ADCC by nivolumab in vitro.
Expression of SYCE2 inhibits the interaction of HP1α with H3K9me3.
Involvement of PI3K activation in TCR/CD3-dependent HIF-1α protein expression. Involvement of PI3K activation in TCR/CD3-dependent HIF-1α protein expression.
Rapamycin inhibits TCR/CD3 engagement-dependent HIF-1α protein expression. Rapamycin inhibits TCR/CD3 engagement-dependent HIF-1α protein expression. Human.
The selective PI3K inhibitor A66 suppresses PIP3 accumulation, AKT phosphorylation at Thr308, and YAP/TAZ–regulated gene expression in PDAC cells. The.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
Dox titration and kinetic analyses of CD19CAR expression upon Dox administration and discontinuation. Dox titration and kinetic analyses of CD19CAR expression.
A, scheme of the APC cDNA and the mutant APC cDNAs which were used for reporter gene assays. A, scheme of the APC cDNA and the mutant APC cDNAs which were.
KIR-CARs/Dap12 trigger robust antigen-specific cytotoxicity in vitro.
Effect of the PD-1–B7-H1 interaction on cell proliferation potential and drug sensitivity in MOSTI-1 cells. Effect of the PD-1–B7-H1 interaction on cell.
Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.
MSLN-targeted RITs in TNBC in vitro.
Mapping the Pirh2 and p73 interaction sites.
pRb turnover in melanoma cells and normal melanocytes.
Consequences of ICAM-1 expression modulation on the lysis of T1 and G1 cells. Consequences of ICAM-1 expression modulation on the lysis of T1 and G1 cells.
Effect of anti-CYP3A and anti-CYP2C antibodies on the disappearance of MPA in human liver microsomes (GHL24). Effect of anti-CYP3A and anti-CYP2C antibodies.
Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.
CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.
Binding and internalization of bispecific immunotoxins.
Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations.
Specific inhibition of the Fab-HLA-A2/Flu induction of CTL mediated tumor cell lysis by a competing antibody. Specific inhibition of the Fab-HLA-A2/Flu.
PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.
The differential susceptibility to CTL-induced lysis does not involve Melan-A antigen expression. The differential susceptibility to CTL-induced lysis.
Effect of SFN on the protein expression of Nrf2, HO-1, and NQO1 in JB6-shMock and JB6-shNrf2 cells. Effect of SFN on the protein expression of Nrf2, HO-1,
IAA inhibits PI3K, MKK4, and MKK7 kinase activities by directly binding in an ATP-competitive manner. IAA inhibits PI3K, MKK4, and MKK7 kinase activities.
Western blotting of PD-L1 mAbs.
The AKT–mTOR pathway controls PD-L1 protein expression.
Characterization of the complex formed at the Fra-1 RCE1.
ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.
IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion. IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion.
Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.
BAF57 binds AR DBD/hinge region.
Intratumoral lymphoid aggregates are sites of postvaccination T-cell activation and regulation. Intratumoral lymphoid aggregates are sites of postvaccination.
IGF-II antibodies inhibited IGF-II-induced phosphorylation of IGF-IR and insulin receptor (IR) in the breast cancer MCF-7 cells. IGF-II antibodies inhibited.
Expression of B7-H1, B7-DC, and PD-1 on B cells.
WP1066 inhibits the progression of OCIM2 cells through the cell cycle.
PD-1 expression in ovarian cancer.
Expression of the cell death markers activated caspase-3 and LC3 I/II in TUBO cells. Expression of the cell death markers activated caspase-3 and LC3 I/II.
Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.
Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.
N1 decoys differently inhibit ligand-induced NOTCH signaling.
AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. AS1411 alters subcellular distribution.
Comparative effect of anti-TIM3 against experimental tumors.
A, TSG-6 staining in human prostate.
Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1 binding. Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1.
Effect of bevacizumab on the proliferation of A2780 cells.
Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.
αvβ6 functional assays in the β cell line using blocking antibodies.
Effect of MIF siRNA on the production of MMP-13 induced by LPA
LDL cholesterol inhibits Vγ9Vδ2 T-cell activation and cytokine production. LDL cholesterol inhibits Vγ9Vδ2 T-cell activation and cytokine production. Preexpanded.
PARP1 suppresses the transcription of PD-L1 in cancer cells.
A, Schematic diagram of identified splice variants of PD-L1.
Expression of chemokine receptors in A-498 cell line.
Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.
MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.
Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.
Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.
Immunohistochemical determination of TIM-3 expression in ccRCC.
Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.
RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Presentation transcript:

B7-1 and PD-1 compete for binding to PD-L1. B7-1 and PD-1 compete for binding to PD-L1. A, 300 cells expressing a chimeric cell surface protein composed of the PD-L1 IgV domain and the TIM-3 mucin, transmembrane, and cytoplasmic domain were incubated with the indicated concentrations of anti–PD-L1 298B.8E2 for 30 minutes, followed by 2.5 μg/mL of PD-1-hIg, B7-1-hIg, or control hIg fusion proteins. Binding of fusion protein was detected with F(ab)2 anti-human IgG PE. Data are representative of two independent experiments. B, 300 hPD-L1-TIM-3 chimera–transfected cells were incubated with the indicated concentrations of B7-1-mIgG2a or mIgG2a. PD-1-hIg fusion protein was added at 2.5μg/mL. The detection reagent was F(ab)2 anti-hIgG PE. Data are representative of two independent experiments. C, 300 hPD-L1-TIM-3 chimera–transfected cells were incubated with the indicated concentrations of hPD-1-hIg or hIg. hB7-1-mIgG2a fusion protein was added at 2.5 μg/mL. The detection reagent was F(ab)2 anti-mIgG2a PE. Data are representative of two independent experiments. Apoorvi Chaudhri et al. Cancer Immunol Res 2018;6:921-929 ©2018 by American Association for Cancer Research